Member Info for ogm4

One question we can already eliminate during the AGM:

Why are you still with Incanthera also?

This chapter has been closed now.

Look at Incanthera price:

https://finance.yahoo.com/quote/INC.AQ/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAMbkSEijysK3fuK3G9JiLVbhJiPecwUsSBE3cdO01HutpnqyhQI33uJbMyh8tWJWz2pXGyuQBei9c4KA7bUc65QaiG4_BrtaseOfZtfW4uxUaiEWaX8T-risLuah35zYksSt5hmCrYgZW0KqePrE033wYekbYaVB3BH94Ay1HomV

It is either neutral or positive news imo.

I guess either he stepped down himself fully on his own behalf or he has been told by IMM stakeholders and/or potential commercial JV partners to fully concentrate on IMM's two main products perhaps also prior any upcoming deals, as these are very busy times for IMM requiring all attention also from the CEO.

"With the appointment of Stuart Robertson as Chief Executive Officer, Mr. Tim McCarthy has stepped down from his position on the board as Executive Chairman with effect from 3 June 2026 in order to concentrate on his other business interests."

Several 1-share trades apppearing

Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study

By James Waldron

Jun 1, 2026 9:26am

https://www.fiercebiotech.com/biotech/agios-agrees-165m-blood-disorder-drug-koreas-oscotec-flunked-phase-2-study

So people are expecting more news then before the AGM 25th end of this month?

Bristol Myers will definitely be looking for replacements of some of their blockbuster products like Eliquis and Opdivo as their patents are expected to expire soon. They will be on the hunt for major cash flow substitutes.

Immupharma is not only Tim CEO.

There is a competent scientific team behind him also doing great research.

Immupharma is not only Tim CEO.

There is a compeyent scientific team behind him also doing great research.

Bristol Myers maybe up for a deal?...

https://www.bms.com/life-and-science/science/rethinking-autoimmune-disease.html

In all fairness there was no real 'new' news in yesterday's RNS we already knew, but then again the final results had to be published at this time of year anyway. Still in discussion with a number of global commercial partners, well we already sort of knew that. Publication of P140 article can't be far off now, but obviously subject to thourough QAQC / confidentiality checks aligned with patent submission.

"We have made meaningful progress in advancing P140 towards late-stage clinical development readiness.

Engagement with regulatory authorities and key stakeholders has been constructive, and we remain committed to ensuring that the next phase of development is robust, efficient, and aligned with regulatory expectations."

Bit of a positive trend today

Reversal coming

Someone also referring to telegram

Some rumours appearing on a d v f n

That's a big buy indeed

1,000,000 shares

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

Published May 8, 2026

By Kelly Bilodeau

https://www.biopharmadive.com/news/lilly-gilead-lead-pharmas-deal-merger-drug-acquisition/819676/

Back to 4.78 again

+15% now?

I guess that must be the large spread